Satellos Bioscience (NASDAQ:MSLE) Announces Earnings Results, Misses Expectations By $0.09 EPS

Satellos Bioscience (NASDAQ:MSLE) issued its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09), Zacks reports.

Satellos Bioscience Stock Up 0.4%

MSLE stock traded up $0.03 during trading on Thursday, hitting $6.78. The company had a trading volume of 37,506 shares, compared to its average volume of 56,068. Satellos Bioscience has a 52-week low of $5.30 and a 52-week high of $13.39. The company has a 50 day simple moving average of $7.86 and a 200-day simple moving average of $8.21. The firm has a market capitalization of $143.82 million, a P/E ratio of -3.52 and a beta of 1.63.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MSLE shares. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Satellos Bioscience in a research note on Monday, August 17th. Craig Hallum initiated coverage on shares of Satellos Bioscience in a research note on Thursday, October 8th. They set a “buy” rating and a $24.00 price target for the company. Zacks Research downgraded shares of Satellos Bioscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.60.

Satellos Bioscience Company Profile

Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.